Article

Alcon submits final NDA for anecortave acetate

Fort Worth, TX—Alcon Laboratories Inc. has submitted the third and final reviewable unit of its new drug application (NDA) for anecortave acetate for depot suspension (Retaane) to the FDA.

Fort Worth, TX-Alcon Laboratories Inc. has submitted the third and final reviewable unit of its new drug application (NDA) for anecortave acetate for depot suspension (Retaane) to the FDA.

Alcon is seeking approval of anecortave acetate for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration.

The drug is an angiostatic steroid delivered as a juxtascleral injection at a dose of 15 mg.

The FDA is reviewing the anecortave acetate NDA under its new Pilot 1 Continuous Marketing Application (CMA) program for fast track-designated products. That program allows designated NDAs to be submitted in specified reviewable units as each is completed.

Alcon filed the Chemistry, Manufacturing, and Controls unit in 2003 and the Pre-Clinical unit in March 2004, and the FDA has completed its initial review of both of those portions. Formal acceptance by the FDA of the third NDA unit can take up to 45 days.

The FDA has also completed its pre-approval inspection of Alcon's manufacturing facility without any negative findings.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.